Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Technology appraisal
Summary (source: NICE)
Reference: TA902
Type: Technology appraisal
Published: 21 June 2023
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction is technology appraisal TA902, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Substances mentioned in this guidance
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 21 June 2023. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.